Search research articles
Contact Us
Filters
Showing results (11-20 of 100) with videos related to
Page
of 10
Sort By:
The Lancet. Oncology
|
February 3, 2022
New EU regulation on health technology assessment of cancer medicines
Thomas J Hwang, Kerstin N Vokinger
JAMA Pediatrics
|
August 12, 2014
New regulatory paradigms for innovative drugs to treat pediatric diseases
Thomas J Hwang, Florence T Bourgeois
American Journal of Law & Medicine
|
November 1, 2017
Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections
Thomas J Hwang, Aaron S Kesselheim
BMJ (Clinical Research Ed.)
|
November 2, 2016
Public referendum on drug prices in the US: will it bring relief?
Thomas J Hwang, Aaron S Kesselheim
JAMA Ophthalmology
|
February 13, 2015
Retinal implants and Medicare reimbursement policies for breakthrough treatments in ophthalmology
Thomas J Hwang, Joseph B Ciolino
JAMA Oncology
|
July 9, 2016
Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model
Thomas J Hwang, John L LaMattina
JAMA Pediatrics
|
November 14, 2017
Improving the Study of New Medicines for Children With Rare Diseases
Florence T Bourgeois, Thomas J Hwang
Health Affairs (Project Hope)
|
February 10, 2016
Vaccine Pipeline Has Grown During The Past Two Decades With More Early-Stage Trials From Small And Medium-Size Companies
Thomas J Hwang, Aaron S Kesselheim
Annals of Internal Medicine
|
January 20, 2016
Breakthrough Medical Devices and the 21st Century Cures Act
Aaron S Kesselheim, Thomas J Hwang
The Lancet. Oncology
|
March 5, 2026
Clinical benefit and the Trump administration's cancer medicine reforms
Thomas J Hwang, Kerstin Noelle Vokinger
Page
of 10
Search research articles
Search
Showing results (11-20 of 100) with videos related to
Sort By:
Page
of 10
The Lancet. Oncology
|
February 3, 2022
New EU regulation on health technology assessment of cancer medicines
Thomas J Hwang, Kerstin N Vokinger
JAMA Pediatrics
|
August 12, 2014
New regulatory paradigms for innovative drugs to treat pediatric diseases
Thomas J Hwang, Florence T Bourgeois
American Journal of Law & Medicine
|
November 1, 2017
Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections
Thomas J Hwang, Aaron S Kesselheim
BMJ (Clinical Research Ed.)
|
November 2, 2016
Public referendum on drug prices in the US: will it bring relief?
Thomas J Hwang, Aaron S Kesselheim
JAMA Ophthalmology
|
February 13, 2015
Retinal implants and Medicare reimbursement policies for breakthrough treatments in ophthalmology
Thomas J Hwang, Joseph B Ciolino
JAMA Oncology
|
July 9, 2016
Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model
Thomas J Hwang, John L LaMattina
JAMA Pediatrics
|
November 14, 2017
Improving the Study of New Medicines for Children With Rare Diseases
Florence T Bourgeois, Thomas J Hwang
Health Affairs (Project Hope)
|
February 10, 2016
Vaccine Pipeline Has Grown During The Past Two Decades With More Early-Stage Trials From Small And Medium-Size Companies
Thomas J Hwang, Aaron S Kesselheim
Annals of Internal Medicine
|
January 20, 2016
Breakthrough Medical Devices and the 21st Century Cures Act
Aaron S Kesselheim, Thomas J Hwang
The Lancet. Oncology
|
March 5, 2026
Clinical benefit and the Trump administration's cancer medicine reforms
Thomas J Hwang, Kerstin Noelle Vokinger
Page
of 10